Table 1

Patient characteristics

CCG, 16 to 20 y, n = 197CALGB, 16 to 20 y, n = 124P
Median age, y 16 19 < .001 
Sex, no. (%) male 129 (65) 87 (70) .45 
Ethnic distribution, no. (%)   .89 
    White 141 (72) 90 (73)  
    Hispanic 32 (16) 19 (15)  
    African-American 13 (7) 10 (8)  
    Other 11 (5) 5 (4)  
Immunophenotype, no. (%), evaluable* 143 92  
    Precursor-T 23 (16) 23 (25) .56 
    Precursor-B 93 (65) 64 (70) .13 
    Other 27 (19) 5 (5) .006 
Cytogenetics, no. (%), evaluable* 67 81  
    t(9;22) 2 (3) 5 (6) .60 
    t(4;11) 2 (3) 2 (2) .75 
Initial WBCs more than 50 × 109/L, no. (%) 47 (24) 26 (21) .64 
CCG, 16 to 20 y, n = 197CALGB, 16 to 20 y, n = 124P
Median age, y 16 19 < .001 
Sex, no. (%) male 129 (65) 87 (70) .45 
Ethnic distribution, no. (%)   .89 
    White 141 (72) 90 (73)  
    Hispanic 32 (16) 19 (15)  
    African-American 13 (7) 10 (8)  
    Other 11 (5) 5 (4)  
Immunophenotype, no. (%), evaluable* 143 92  
    Precursor-T 23 (16) 23 (25) .56 
    Precursor-B 93 (65) 64 (70) .13 
    Other 27 (19) 5 (5) .006 
Cytogenetics, no. (%), evaluable* 67 81  
    t(9;22) 2 (3) 5 (6) .60 
    t(4;11) 2 (3) 2 (2) .75 
Initial WBCs more than 50 × 109/L, no. (%) 47 (24) 26 (21) .64 

WBC indicates white blood cell.

*

Patients were reviewed and confirmed by central cooperative group pathology and cytogenetic committees.

Different criteria were used by CCG and CALGB to characterize the immunophenotype and may account for the differences in numbers of patients in the ″other″ category. For CCG, the ″other″ category includes patients with coexpression of both B and T markers on lymphoblasts (14 patients) and 13 patients where the immunophenotype could not be fully resolved. For CALGB, only patients with coexpression of B and T markers were included in the ″other″ category.

or Create an Account

Close Modal
Close Modal